R R Reinhardt
Overview
Explore the profile of R R Reinhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leiter L, Mallory J, Wilson T, Reinhardt R
Diabetes Obes Metab
. 2016 Apr;
18(9):930-5.
PMID: 27097971
Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment-related AEs associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of type 2 diabetes mellitus. The GI safety...
2.
Hompesch M, Jones-Leone A, Carr M, Matthews J, Zhi H, Young M, et al.
Diabetes Obes Metab
. 2014 Sep;
17(1):82-90.
PMID: 25263215
Aim: To determine if the glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide, once weekly, impairs counter-regulatory responses during hypoglycaemia. Methods: We conducted a randomized, double-blind, parallel, placebo-controlled study in subjects with...
3.
Reusch J, Stewart M, Perkins C, Cirkel D, Ye J, Perry C, et al.
Diabetes Obes Metab
. 2014 Aug;
16(12):1257-64.
PMID: 25155146
Aims: To show that albiglutide, a glucagon-like peptide-1 receptor agonist, is an effective and generally safe treatment to improve glycaemic control in patients with type 2 diabetes mellitus whose hyperglycaemia...
4.
Cocquyt V, Van Belle S, Reinhardt R, Decramer M, OBrien M, Schellens J, et al.
Eur J Cancer
. 2001 Apr;
37(7):835-42.
PMID: 11313170
Substance P is localised in brainstem regions associated with emesis. Based on studies in the ferret, it was postulated that a neurokinin-1 (NK1) receptor antagonist would have antiemetic activity as...
5.
Campos D, Pereira J, Reinhardt R, Carracedo C, Poli S, Vogel C, et al.
J Clin Oncol
. 2001 Mar;
19(6):1759-67.
PMID: 11251007
Purpose: The NK1-receptor antagonist MK-869 (L-754,030) has demonstrated antiemetic activity in humans receiving chemotherapy. Objectives of the present trial included the first assessment of oral MK-869 plus dexamethasone compared with...
6.
Cheng C, Reinhardt R, Lee W, JONCAS G, Patel S, Bondy C
Proc Natl Acad Sci U S A
. 2000 Aug;
97(18):10236-41.
PMID: 10954733
The brain has enormous anabolic needs during early postnatal development. This study presents multiple lines of evidence showing that endogenous brain insulin-like growth factor 1 (Igf1) serves an essential, insulin-like...
7.
Navari R, Reinhardt R, Gralla R, Kris M, Hesketh P, Khojasteh A, et al.
N Engl J Med
. 1999 Jan;
340(3):190-5.
PMID: 9917226
Background: The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an...
8.
Cheng C, JONCAS G, Reinhardt R, Farrer R, Quarles R, Janssen J, et al.
J Neurosci
. 1998 Jul;
18(15):5673-81.
PMID: 9671658
To elucidate the role of insulin-like growth factor 1 (IGF1) in the normal development of brain myelination, we used behavioral, biochemical, and histological analyses to compare the myelination of brains...
9.
Reinhardt R, Bondy C
Neuroscience
. 1996 May;
72(2):567-78.
PMID: 8737425
Cyclic GMP-inhibited phosphodiesterases are characterized by sensitivity of cAMP hydrolysis to inhibition by cGMP. This phosphodiesterase family contains at least two different isoforms (PDE3A and PDE3B) encoded by distinct genes...
10.
Reinhardt R, Chin E, Zhou J, Taira M, Murata T, Manganiello V, et al.
J Clin Invest
. 1995 Apr;
95(4):1528-38.
PMID: 7706458
Type III cGMP-inhibited phosphodiesterases (PDE3s) play important roles in hormonal regulation of lipolysis, platelet aggregation, myocardial contractility, and smooth muscle relaxation. We have recently characterized two PDE3 subtypes (PDE3A and...